COMMUNIQUÉS West-GlobeNewswire

HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy
19/05/2026
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead [...]
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
19/05/2026
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
19/05/2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence [...]
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
19/05/2026
BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire [...]
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
19/05/2026
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages Primary results from the persevERA study on the numerical [...]
Unaudited Preliminary Results for the Year Ended December 31, 2025
19/05/2026
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery [...]
Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
19/05/2026
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise NIJMEGEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- Khondrion today [...]
Rapid Nutrition Advances Finalization of Australian Flagship Initiative
19/05/2026
LONDON, May 19, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition brands, is pleased to provide an update regarding its Australian [...]
Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises” for AI‑Powered Chronic Disease Services
19/05/2026
GUANGZHOU, China, May 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to attend the 2026 Guangzhou [...]
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
19/05/2026
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to [...]
Pennant Group to Participate in the 2026 RBC Global Healthcare Conference
19/05/2026
EAGLE, Idaho, May 18, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will [...]
Certara to Participate in Upcoming Investor Conferences
18/05/2026
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
18/05/2026
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 [...]
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
18/05/2026
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
18/05/2026
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an [...]

Pages